Top

Published in:

Open Access 01-12-2014

MTA1—a stress response protein: a master regulator of gene expression and cancer cell behavior

Author: Rui-An Wang

Published in: Cancer and Metastasis Reviews | Issue 4/2014

Abstract

Gene mutation’s role in initiating carcinogenesis has been controversial, but it is consensually accepted that both carcinogenesis and cancer metastasis are gene-regulated processes. MTA1, a metastasis-associated protein, has been extensively researched, especially regarding its role in cancer metastasis. In this review, I try to elucidate MTA1’s role in both carcinogenesis and metastasis from a different angle. I propose that MTA1 is a stress response protein that is upregulated in various stress-related situations such as heat shock, hypoxia, and ironic radiation. Cancer cells are mostly living in a stressful environment of hypoxia, lack of nutrition, and immune reaction attacks. To cope with all these stresses, MTA1 expression is upregulated, plays a role of master regulator of gene expression, and helps cancer cells to survive and migrate out of their original dwelling.

Wang, R. A., Li, Z. S., Zhang, H. Z., Zheng, P. J., Li, Q. L., Shi, J. G., et al. (2013). Invasive cancers are not necessarily from preformed in situ tumours—an alternative way of carcinogenesis from misplaced stem cells. Journal of Cellular and Molecular Medicine, 17, 921–926.PubMed

Baker, S. G. (2012/2013). Paradox-driven cancer research. Disruptive Science and Technology, 1, 143–148.

Soto, A. M., & Sonnenschein, C. (2011). The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. Bioessays, 33, 332–340.PubMedCentralPubMed

Duesberg, P. (2005). Does aneuploidy or mutation start cancer? Science, 307, 41.PubMed

Meng, X., Zhong, J., Liu, S., Murray, M., & Gonzalez-Angulo, A. M. (2012). A new hypothesis for the cancer mechanism. Cancer Metastasis Review, 31, 247–268.

Weinberg, R. A. (2014). Coming full circle-from endless complexity to simplicity and back again. Cell, 157, 267–271.PubMed

Turkalp, Z., Karamchandani, J., & Das, S. (2014). IDH Mutation in. Glioma: New insights and promises for the future. JAMA Neurology. doi:10.1001/jamaneurol.2014.1205.

Gorovets, D., Kannan, K., Shen, R., Kastenhuber, E. R., Islamdoust, N., Campos, C., et al. (2012). IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clinical Cancer Research, 18, 2490–2501.PubMed

Qi, S. T., Yu, L., Lu, Y. T., Ou, Y. H., Li, Z. Y., Wu, L. X., et al. (2011). IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. Oncology Reports, 26, 1479–1485.PubMed

10.

Hong, J. W., Lee, S., Kim, D. C., Kim, K. H., & Song, K. H. (2014). Prognostic and clinicopathologic associations of BRAF mutation in primary acral lentiginous melanoma in Korean patients: a preliminary study. Annals of Dermatology, 26, 195–202.PubMedCentralPubMed

11.

Broders, A. C. (1932). Carcinoma in situ contrasted with benign penetrating epithelium. JAMA-Journal of The American Medical Association, 99, 1670–1674.

12.

Burstein, H. J., Polyak, K., Wong, J. S., Lester, S. C., & Kaelin, C. M. (2004). Ductal carcinoma in situ of the breast. New England Journal of Medicine, 350, 1430–1441.PubMed

13.

Latta, E. K., Tjan, S., Parkes, R. K., & O’Malley, F. P. (2002). The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Modern Pathology, 15, 1318–1325.PubMed

14.

Barnes, D. M., Bartkova, J., Camplejohn, R. S., Gullick, W. J., Smith, P. J., & Millis, R. R. (1992). Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? European Journal of Cancer, 28, 644–648.PubMed

15.

Allred, D. C., Clark, G. M., Molina, R., Tandon, A. K., Schnitt, S. J., Gilchrist, K. W., et al. (1992). Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human Pathology, 23, 974–979.PubMed

16.

Frykberg, E. R. (1999). Lobular carcinoma in situ of the breast. Breast Journal, 5, 296–303.PubMed

17.

Sanders, M. E., Schuyler, P. A., Dupont, W. D., & Page, D. L. (2005). The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer, 103, 2481–2484.PubMed

18.

Virnig, B. A., Wang, S. Y., Shamilyan, T., Kane, R. L., & Tuttle, T. M. (2010). Ductal carcinoma in situ: risk factors and impact of screening. Journal of National Cancer Institute Monographs, 2010, 113–116.

19.

Wang, R. A., Li, Z. S., Yan, Q. G., Bian, X. W., Ding, Y. Q., Du, X., et al. (2014). Resistance to apoptosis should not be taken as a hallmark of cancer. Chinese Journal of Cancer, 33, 47–50.PubMedCentralPubMed

20.

Baker, S. G. (2012). Paradoxes in carcinogenesis should spur new avenues of research: an historical perspective. Disruptive Sciences and Technology., 1, 100–107.

21.

Miller, F. R., Santner, S. J., Tait, L., & Dawson, P. J. (2000). MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. Journal of National Cancer Institute, 92, 1185–1186.

22.

Wang, R. A., Li, Q. L., Li, Z. S., Zheng, P. J., Zhang, H. Z., Huang, X. F., et al. (2013). Apoptosis drives cancer cells proliferate and metastasize. Journal of Cellular and Molecular Medecine, 17, 205–211.

23.

Lipponen, P., Aaltomaa, S., Kosma, V. M., & Syrjanen, K. (1994). Apoptosis in breast cancer as related to histopathological characteristics and prognosis. European Journal of Cancer, 30A, 2068–2073.PubMed

24.

Lipponen, P. K., & Aaltomaa, S. (1994). Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. Journal of Pathology, 173, 333–339.PubMed

25.

Zhang, G. J., Kimijima, I., Abe, R., Watanabe, T., Kanno, M., Hara, K., et al. (1998). Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Research, 18, 1989–1998.PubMed

26.

Sinicrope, F. A., Hart, J., Hsu, H. A., Lemoine, M., Michelassi, F., & Stephens, L. C. (1999). Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clinical Cancer Research, 5, 1793–1804.PubMed

27.

Lipponen, P. (1999). Apoptosis in breast cancer: relationship with other pathological parameters. Endocrine Related Cancer, 6, 13–16.PubMed

28.

Nishimura, R., Nagao, K., Miyayama, H., Matsuda, M., Baba, K., Matsuoka, Y., et al. (1999). Apoptosis in breast cancer and its relationship to clinicopathological characteristics and prognosis. Journal of Surgical Oncology, 71, 226–234.PubMed

29.

Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57–70.PubMed

30.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144, 646–674.PubMed

31.

Kuo, C. Y., Tsai, J. I., Chou, T. Y., Hung, M. J., Wu, C. C., Hsu, S. L., et al. (2012). Apoptosis induced by hepatitis B virus X protein in a CCL13-HBx stable cell line. Oncology Reports, 28, 127–132.PubMed

32.

Tang, R. X., Kong, F. Y., Fan, B. F., Liu, X. M., You, H. J., Zhang, P., et al. (2012). HBx activates FasL and mediates HepG2 cell apoptosis through MLK3-MKK7-JNKs signal module. World Journal of Gastroenterology, 18, 1485–1495.PubMedCentralPubMed

33.

Hu, L., Chen, L., Yang, G., Li, L., Sun, H., Chang, Y., et al. (2011). HBx sensitizes cells to oxidative stress-induced apoptosis by accelerating the loss of Mcl-1 protein via caspase-3 cascade. Molecular Cancer, 10, 43.PubMedCentralPubMed

34.

Kim, J. Y., Song, E. H., Lee, H. J., Oh, Y. K., Choi, K. H., Yu, D. Y., et al. (2010). HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways. Journal of Molecular Biology, 397, 917–931.PubMed

35.

Cheng, P., Li, Y., Yang, L., Wen, Y., Shi, W., Mao, Y., et al. (2009). Hepatitis B virus X protein (HBx) induces G2/M arrest and apoptosis through sustained activation of cyclin B1-CDK1 kinase. Oncology Reports, 22, 1101–1107.PubMed

36.

Niu, D., Zhang, J., Ren, Y., Feng, H., & Chen, W. N. (2009). HBx genotype D represses GSTP1 expression and increases the oxidative level and apoptosis in HepG2 cells. Molecular Oncology, 3, 67–76.PubMed

37.

Tanaka, Y., Kanai, F., Kawakami, T., Tateishi, K., Ijichi, H., Kawabe, T., et al. (2004). Interaction of the hepatitis B virus X protein (HBx) with heat shock protein 60 enhances HBx-mediated apoptosis. Biochemical and Biophysical Research Communication, 318, 461–469.

38.

Su, F., Theodosis, C. N., & Schneider, R. J. (2001). Role of NF-kappaB and myc proteins in apoptosis induced by hepatitis B virus HBx protein. Journal of Virology, 75, 215–225.PubMedCentralPubMed

39.

Chen, L., Park, S. M., Tumanov, A. V., Hau, A., Sawada, K., Feig, C., et al. (2010). CD95 promotes tumour growth. Nature, 465, 492–496.PubMedCentralPubMed

40.

Huang, Q., Li, F., Liu, X., Li, W., Shi, W., Liu, F. F., et al. (2011). Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nature Medicine, 17, 860–866.PubMedCentralPubMed

41.

Sun, K., Guo, X. L., Zhao, Q. D., Jing, Y. Y., Kou, X. R., Xie, X. Q., et al. (2013). Paradoxical role of autophagy in the dysplastic and tumor-forming stages of hepatocarcinoma development in rats. Cell Death and Disease, 4, e501.PubMedCentralPubMed

42.

Murphy, K. L., Kittrell, F. S., Gay, J. P., Jager, R., Medina, D., & Rosen, J. M. (1999). Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice. Oncogene, 18, 6597–6604.PubMed

43.

Knowlton, K., Mancini, M., Creason, S., Morales, C., Hockenbery, D., & Anderson, B. O. (1998). Bcl-2 slows in vitro breast cancer growth despite its antiapoptotic effect. Journal of Surgical Research, 76, 22–26.PubMed

44.

de La Coste, A., Mignon, A., Fabre, M., Gilbert, E., Porteu, A., Van Dyke, T., et al. (1999). Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice. Cancer Research, 59, 5017–5022.

45.

Yang, Q., Sakurai, T., Yoshimura, G., Suzuma, T., Umemura, T., Nakamura, M., et al. (2003). Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncology Reports, 10, 121–125.PubMed

46.

Callagy, G. M., Pharoah, P. D., Pinder, S. E., Hsu, F. D., Nielsen, T. O., Ragaz, J., et al. (2006). Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clinical Cancer Research, 12, 2468–2475.PubMed

47.

Lee, K. H., Im, S. A., Oh, D. Y., Lee, S. H., Chie, E. K., Han, W., et al. (2007). Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer, 7, 63.PubMedCentralPubMed

48.

Rolland, P., Spendlove, I., Madjd, Z., Rakha, E. A., Patel, P., Ellis, I. O., et al. (2007). The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. International Journal of Cancer, 120, 1311–1317.

49.

Poincloux, L., Durando, X., Seitz, J. F., Thivat, E., Bardou, V. J., Giovannini, M. H., et al. (2009). Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. Surgical Oncology-Oxford, 18, 357–365.

50.

Watson, N. F., Madjd, Z., Scrimegour, D., Spendlove, I., Ellis, I. O., Scholefield, J. H., et al. (2005). Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients. World Journal of Surgical Oncology, 3, 47.PubMedCentralPubMed

51.

Tomita, M., Matsuzaki, Y., Edagawa, M., Shimizu, T., Hara, M., & Onitsuka, T. (2003). Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer. European Journal of Surgical Oncology, 29, 654–657.PubMed

52.

Yang, C., Davis, J. L., Zeng, R., Vora, P., Su, X., Collins, L. I., et al. (2013). Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Cancer Discovery, 3, 212–223.PubMedCentralPubMed

53.

Ebos, J. M., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell, 15, 232–239.PubMed

54.

Paez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Vinals, F., et al. (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell, 15, 220–231.PubMedCentralPubMed

55.

Bouchard, G., Bouvette, G., Therriault, H., Bujold, R., Saucier, C., & Paquette, B. (2013). Pre-irradiation of mouse mammary gland stimulates cancer cell migration and development of lung metastases. British Journal of Cancer, 109, 1829–1838.PubMedCentralPubMed

56.

Pani, G., Galeotti, T., & Chiarugi, P. (2010). Metastasis: cancer cell’s escape from oxidative stress. Cancer Metastasis Review, 29, 351–378.

57.

PREHN, R. T., & MAIN, J. M. (1957). Immunity to methylcholanthrene-induced sarcomas. Journal National Cancer Institute, 18, 769–778.

58.

Wang, R. A., & Yan, Q. G. (2013). Adaptation biology and medicine (pp. 129–136). New Delhi: Narosa Publishing House.

59.

Cairns, J. (1980). Efficiency of the adaptive response of Escherichia coli to alkylating agents. Nature, 286, 176–178.PubMed

60.

Wu, J., Rosenbaum, E., Begum, S., & Westra, W. H. (2007). Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. American Journal of Dermatopathology, 29, 534–537.PubMed

61.

Baserga, R. (1965). The relationship of the cell cycle to tumor growth and control of cell division: a review. Cancer Research, 25, 581–595.PubMed

62.

Toh, Y., Pencil, S. D., & Nicolson, G. L. (1994). A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. Journal of Biological Chemistry, 269, 22958–22963.PubMed

63.

Toh, Y., Oki, E., Oda, S., Tokunaga, E., Ohno, S., Maehara, Y., et al. (1997). Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. International Journal of Cancer, 74, 459–463.

64.

Toh, Y., Kuwano, H., Mori, M., Nicolson, G. L., & Sugimachi, K. (1999). Overexpression of metastasis-associated MTA1 mRNA in invasive oesophageal carcinomas. British Journal of Cancer, 79, 1723–1726.PubMedCentralPubMed

65.

Liang, Y., Dong, Y., Zhao, J., & Li, W. (2013). YES1 activation elicited by heat stress is anti-apoptotic in mouse pachytene spermatocytes. Biology of Reproduction, 89, 131.PubMed

66.

Bui-Nguyen, T. M., Pakala, S. B., Sirigiri, R. D., Xia, W., Hung, M. C., Sarin, S. K., et al. (2010). NF-kappaB signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx. Oncogene, 29, 1179–1189.PubMedCentralPubMed

67.

Li, W., Wu, Z. Q., Zhao, J., Guo, S. J., Li, Z., Feng, X., et al. (2011). Transient protection from heat-stress induced apoptotic stimulation by metastasis-associated protein 1 in pachytene spermatocytes. PLoS One, 6, e26013.PubMedCentralPubMed

68.

Li, W., Bao, W., Ma, J., Liu, X., Xu, R., Wang, R. A., et al. (2008). Metastasis tumor antigen 1 is involved in the resistance to heat stress-induced testicular apoptosis. FEBS Letters, 582, 869–873.PubMed

69.

Yoo, Y. G., Kong, G., & Lee, M. O. (2006). Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO Journal, 25, 1231–1241.PubMedCentralPubMed

70.

Ohshiro, K., Reddy, S. D., Pakala, S. B., Lee, M. H., Zhang, Y., et al. (2009). E3 ubiquitin ligase COP1 regulates the stability and functions of MTA1. Proceedings of the National Academy of Sciences of USA, 106, 17493–17498.

71.

Li, D. Q., Divijendra, N. R. S., Pakala, S. B., Wu, X., Zhang, Y., Rayala, S. K., et al. (2009). MTA1 coregulator regulates p53 stability and function. Journal of Biological Chemistry, 284, 34545–34552.PubMedCentralPubMed

72.

Li, D. Q., Ohshiro, K., Khan, M. N., & Kumar, R. (2010). Requirement of MTA1 in ATR-mediated DNA damage checkpoint function. Journal of Biological Chemistry, 285, 19802–19812.PubMedCentralPubMed

73.

Pakala, S. B., Bui-Nguyen, T. M., Reddy, S. D., Li, D. Q., Peng, S., Rayala, S. K., et al. (2010). Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis. Journal of Biological Chemistry, 285, 23590–23597.PubMedCentralPubMed

74.

Mazumdar, A., Wang, R. A., Mishra, S. K., Adam, L., Bagheri-Yarmand, R., Mandal, M., et al. (2001). Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nature Cell Biology, 3, 30–37.PubMed

75.

Motavaf, M., Safari, S., Saffari, J. M., & Alavian, S. M. (2013). Hepatitis B virus-induced hepatocellular carcinoma: the role of the virus x protein. Acta Virologica, 57, 389–396.PubMed

76.

Yoo, Y. G., Na, T. Y., Seo, H. W., Seong, J. K., Park, C. K., Shin, Y. K., et al. (2008). Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene, 27, 3405–3413.PubMed

77.

Xin, B., Wang, X. Y., Li, Y., Qin, J. H., Ma, X. J., Yin, J. P., et al. (2012). Expression and potential role of metastasis-associated protein 1 in the induced carcinogenesis of mouse liver. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi(Chinese), 28, 801–803.

78.

Hofer, M. D., Tapia, C., Browne, T. J., Mirlacher, M., Sauter, G., & Rubin, M. A. (2006). Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue. Archives of Pathology and Laboratory Medicine, 130, 989–996.PubMed

79.

Luo, H., Li, H., Yao, N., Hu, L., & He, T. (2014). Metastasis-associated protein 1 as a new prognostic marker for solid tumors: a meta-analysis of cohort studies. Tumour Biology, 35, 5823–5832.PubMed

80.

Jang, K. S., Paik, S. S., Chung, H., Oh, Y. H., & Kong, G. (2006). MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Science, 97, 374–379.PubMed

81.

Zhang, H., Stephens, L. C., & Kumar, R. (2006). Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clinical Cancer Research, 12, 1479–1486.PubMed

82.

Martin, M. D., Hilsenbeck, S. G., Mohsin, S. K., Hopp, T. A., Clark, G. M., Osborne, C. K., et al. (2006). Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Research and Treatment, 95, 7–12.PubMed

83.

Cheng, C. W., Liu, Y. F., Yu, J. C., Wang, H. W., Ding, S. L., Hsiung, C. N., et al. (2012). Prognostic significance of cyclin D1, beta-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast. Annals of Surgical Oncology, 19, 4129–4139.PubMed

84.

Higashijima, J., Kurita, N., Miyatani, T., Yoshikawa, K., Morimoto, S., Nishioka, M., et al. (2011). Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer. Oncology Reports, 26, 343–348.PubMed

85.

Li, S. H., Wang, Z., & Liu, X. Y. (2009). Metastasis-associated protein 1 (MTA1) overexpression is closely associated with shorter disease-free interval after complete resection of histologically node-negative esophageal cancer. World Journal of Surgery, 33, 1876–1881.PubMed

86.

Sasaki, H., Moriyama, S., Nakashima, Y., Kobayashi, Y., Yukiue, H., Kaji, M., et al. (2002). Expression of the MTA1 mRNA in advanced lung cancer. Lung Cancer, 35, 149–154.PubMed

87.

Xu, L., Mao, X. Y., Fan, C. F., & Zheng, H. C. (2011). MTA1 expression correlates significantly with cigarette smoke in non-small cell lung cancer. Virchows Archiv: an International Journal of Pathology, 459, 415–422.

88.

Hamatsu, T., Rikimaru, T., Yamashita, Y., Aishima, S., Tanaka, S., Shirabe, K., et al. (2003). The role of MTA1 gene expression in human hepatocellular carcinoma. Oncology Reports, 10, 599–604.PubMed

89.

Moon, W. S., Chang, K., & Tarnawski, A. S. (2004). Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: relationship to vascular invasion and estrogen receptor-alpha. Human Pathology, 35, 424–429.PubMed

90.

Sasaki, H., Yukiue, H., Kobayashi, Y., Nakashima, Y., Kaji, M., Fukai, I., et al. (2001). Expression of the MTA1 mRNA in thymoma patients. Cancer Letters, 174, 159–163.PubMed

91.

Murakami, M., Kaul, R., & Robertson, E. S. (2008). MTA1 expression is linked to ovarian cancer. Cancer Biology & Therapy, 7, 1468–1470.

92.

Prisco, M. G., Zannoni, G. F., De Stefano, I., Vellone, V. G., Tortorella, L., Fagotti, A., et al. (2012). Prognostic role of metastasis tumor antigen 1 in patients with ovarian cancer: a clinical study. Human Pathology, 43, 282–288.PubMed

93.

Deng, Y. F., Zhou, D. N., Ye, C. S., Zeng, L., & Yin, P. (2012). Aberrant expression levels of MTA1 and RECK in nasopharyngeal carcinoma: association with metastasis, recurrence, and prognosis. The Annals of Otology, Rhinology and Laryngology, 121, 457–465.

94.

Song, L., Wang, Z., & Liu, X. (2013). MTA1: a prognosis indicator of postoperative patients with esophageal carcinoma. The Thoracic and Cardiovascular Surgeons, 61, 479–485.

95.

Iguchi, H., Imura, G., Toh, Y., & Ogata, Y. (2000). Expression of MTA1, a metastasis-associated gene with histone deacetylase activity in pancreatic cancer. International Journal of Oncology, 16, 1211–1214.PubMed

96.

Hofer, M. D., Chang, M. C., Hirko, K. A., Rubin, M. A., & Nose, V. (2009). Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors. Modern Pathology, 22, 933–939.PubMed

97.

Hofer, M. D., Kuefer, R., Varambally, S., Li, H., Ma, J., Shapiro, G. I., et al. (2004). The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Research, 64, 825–829.PubMed

98.

Dias, S. J., Zhou, X., Ivanovic, M., Gailey, M. P., Dhar, S., Zhang, L., et al. (2013). Nuclear MTA1 overexpression is associated with aggressive prostate cancer, recurrence and metastasis in African Americans. Scientific Report, 3, 2331.

99.

Bruning, A., Makovitzky, J., Gingelmaier, A., Friese, K., & Mylonas, I. (2009). The metastasis-associated genes MTA1 and MTA3 are abundantly expressed in human placenta and chorionic carcinoma cells. Histochemistry and Cell Biology, 132, 33–38.PubMed

100.

Manavathi, B., Peng, S., Rayala, S. K., Talukder, A. H., Wang, M. H., Wang, R. A., et al. (2007). Repression of Six3 by a corepressor regulates rhodopsin expression. Proceedings of the National Academy of Sciences of the United States of America, 104, 13128–13133.PubMedCentralPubMed

101.

Kumar, R., Balasenthil, S., Manavathi, B., Rayala, S. K., & Pakala, S. B. (2010). Metastasis-associated protein 1 and its short form variant stimulates Wnt1 transcription through promoting its derepression from Six3 corepressor. Cancer Research, 70, 6649–6658.PubMedCentralPubMed

102.

Pakala, S. B., Singh, K., Reddy, S. D., Ohshiro, K., Li, D. Q., Mishra, L., et al. (2011). TGF-beta1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells. Oncogene, 30, 2230–2241.PubMedCentralPubMed

103.

Moon, H. E., Cheon, H., & Lee, M. S. (2007). Metastasis-associated protein 1 inhibits p53-induced apoptosis. Oncology Reports, 18, 1311–1314.PubMed

104.

Choubey, D. (2000). P202: an interferon-inducible negative regulator of cell growth. Journal of Biological Regulators and Homeostatic Agents, 14, 187–192.PubMed

105.

Yan, D. H., Wen, Y., Spohn, B., Choubey, D., Gutterman, J. U., & Hung, M. C. (1999). Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202. Oncogene, 18, 807–811.PubMed

106.

Li, D. Q., Pakala, S. B., Reddy, S. D., Peng, S., Balasenthil, S., Deng, C. X., et al. (2013). Metastasis-associated protein 1 is an integral component of the circadian molecular machinery. Nature Communications, 4, 2545.PubMed

107.

Pakala, S. B., Rayala, S. K., Wang, R. A., Ohshiro, K., Mudvari, P., Reddy, S. D., et al. (2013). MTA1 promotes STAT3 transcription and pulmonary metastasis in breast cancer. Cancer Research, 73, 3761–3770.PubMedCentralPubMed

Title: MTA1—a stress response protein: a master regulator of gene expression and cancer cell behavior
Author: Rui-An Wang
Publication date: 01-12-2014
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 4/2014
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-014-9525-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Biography—Rakesh Kumar, Ph.D.

Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art

Role of MTA1 in head and neck cancers

Erratum to: Emerging strategies to overcome resistance to endocrine therapy for breast cancer

Metastatic tumor antigen in hepatocellular carcinoma: golden roads toward personalized medicine

E-cadherin germline mutation carriers: clinical management and genetic implications

Keynote webinar | Spotlight on antibody–drug conjugates in cancer